Bisirna Therapeutics (suzhou) Co., Ltd.

This early-stage study tests VSA012, a drug that targets the complement system (part of the immune system), in 40 healthy volunteers. The main goal is to check safety and how the drug moves through the body after a single dose. It is a first step before testing in patients with c…